Welcome to our dedicated page for Pro-Dex Colo news (Ticker: PDEX), a resource for investors and traders seeking the latest updates and insights on Pro-Dex Colo stock.
Pro-Dex, Inc. (NASDAQ: PDEX) is a surgical and medical instrument manufacturer that focuses on autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used mainly in the orthopedic, thoracic, and maxocranial facial markets. The Pro-Dex news stream on this page aggregates company-issued press releases and other coverage so readers can follow how its powered surgical instrument business develops over time.
Company news frequently centers on financial results and operating performance. Pro-Dex regularly announces quarterly and annual results, often highlighting changes in net sales, gross profit, operating income, and the impact of product mix and costs such as tariffs. These updates commonly explain how shipments of next generation orthopedic handpieces, repair revenue for legacy handpieces, and sales of thoracic drivers contribute to revenue trends, especially in relation to the company’s largest customer.
Another recurring theme in Pro-Dex news is customer and contract activity. The company has reported contract amendments and extensions with its largest customer, including multi-year extensions with minimum purchase volumes. Releases also discuss enhanced repair programs for orthopedic handpieces and the ramp-up of production shipments for new generations of devices.
Pro-Dex news items may also cover corporate governance and capital matters, such as proxy statements, annual shareholder meetings, equity incentive plan amendments, and executive or director compensation decisions disclosed via Form 8-K. In addition, the company has issued communications clarifying that its Nasdaq-listed common stock under the symbol PDEX is not affiliated with Polkadex, which uses the same symbol on certain crypto exchanges.
Investors and followers of PDEX can use this page to review a chronological record of Pro-Dex announcements, including earnings releases, contract updates, and governance disclosures, all in one place.
Pro-Dex (NasdaqCM: PDEX) announced a contract amendment with its largest customer executed on December 17, 2025 that extends an agreement scheduled to terminate on December 31, 2025 through December 31, 2028. The amendment includes minimum purchase volumes for 2026 and 2027, and continues a commercial relationship that will total more than fifteen years.
The company makes autoclavable, battery-powered and electric surgical drivers and shavers, licensed torque-limiting software, and sells rotary air motors (described as a de minimis portion of revenue). Management framed the amendment as positioning Pro-Dex for continued revenue growth.
Pro-Dex (Nasdaq: PDEX) reported fiscal 2026 first quarter results for the period ended September 30, 2025. Net sales rose 24% to $18.5M, driven mainly by resumption of shipments of a next-generation handpiece to the company's largest customer. Gross margin fell 6 percentage points to 29% due to higher costs and tariffs. Operating income was $3.1M and net income was $4.68M ($1.40 diluted), which included $3.3M of unrealized investment gains. The company received $8.9M cash from the sale of Monogram shares and filed its Form 10-Q on October 30, 2025.
Pro-Dex (NasdaqCM: PDEX) issued a market clarification on October 16, 2025 to help avoid confusion between its Nasdaq-listed common stock and an unrelated crypto entity using the PDEX symbol. The company emphasized there is no relationship or affiliation with Polkadex and urged investors to verify whether research or trades referencing PDEX relate to Pro-Dex or to Polkadex.
Pro-Dex designs and manufactures autoclavable, battery-powered, and electric multi-function surgical drivers and shavers for orthopedic, thoracic, and maxocranial facial markets, and sells rotary air motors that represent a de minimis portion of revenue. Contact: Richard L. Van Kirk, CEO, (949) 769-3200.
Pro-Dex (NASDAQ:PDEX), a manufacturer of surgical drivers and shavers, reported its fiscal 2025 Q4 and full-year results. Annual net sales increased 24% to $66.6 million, driven by next-generation handpiece sales to their largest customer. Full-year net income surged to $9.0 million ($2.67 per diluted share), up from $2.1 million ($0.60 per diluted share) in fiscal 2024.
Q4 net sales grew 16% to $17.5 million, though gross margin declined from 27% to 20% due to unfavorable product mix and tariff costs. The company reported a strong backlog of $50.4 million as of June 30, 2025, and management expects continued revenue and operating income growth in fiscal 2026.
Pro-Dex (PDEX) reported strong financial results for Q2 FY2025. Net sales increased 33% to $16.8 million, driven by $3.1 million in shipments of next-generation orthopedic handpieces and $1.6 million increase in repair revenue from their largest customer.
Gross profit rose 81% to $5.1 million, with gross margin improving by 8 percentage points to 30%. Operating income surged 247% to $2.7 million, while net income reached $2.0 million ($0.61 per diluted share), up from $500,000 ($0.14 per diluted share) in Q2 FY2024.
For the six-month period, net sales grew 29% to $31.7 million, with net income of $4.5 million ($1.33 per diluted share), compared to a net loss of $115,000 in the prior year period. The company expects continued revenue growth in Q3 and Q4 due to ongoing production shipments of the next-generation handpiece.
Pro-Dex (NASDAQ:PDEX) reported strong financial results for Q1 FY2025. Net sales increased 25% to $14.9 million, driven by increased repairs and shipment of next-generation handpiece. Gross profit rose 41% with margin expanding to 35%. Operating income grew 64% to $3.0 million. Net income improved to $2.5 million ($0.75 per diluted share) from a net loss of $615,000 in the prior year. The company expects to ship production volumes of the new handpiece during second half of fiscal year.
Pro-Dex (NASDAQ:PDEX) reported strong financial results for Q4 and FY 2024. Q4 net sales increased 41% to $15.0 million, driven by a $3.4 million revenue boost from their largest customer. Q4 operating income rose 46% to $2.4 million. FY 2024 net sales grew 17% to $53.8 million, with operating income up 25% to $7.2 million. However, net income for FY 2024 decreased to $2.1 million ($0.60 per diluted share) from $7.1 million in FY 2023, primarily due to unrealized losses on marketable equity investments. The company highlighted successful growth despite transitioning to a multiple-facility operation and announced the hiring of a new Director of Operations to support future expansion.
Pro-Dex, Inc. reported strong fiscal 2024 third quarter and nine-month results with increases in net sales and operating income. However, net income declined due to unrealized losses on marketable equity investments. The company remains optimistic about future growth.
FAQ
What is the current stock price of Pro-Dex Colo (PDEX)?
What is the market cap of Pro-Dex Colo (PDEX)?
